|
07 Jan 2023 |
HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603
|
|
07 Jan 2023 |
Dragonfly Therapeutics Announces Sixth Dragonfly TriNKET Opt-in by Bristol Myers Squibb
|
|
07 Jan 2023 |
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
|
|
07 Jan 2023 |
FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
|
|
06 Jan 2023 |
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children
|
|
06 Jan 2023 |
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
|
|
06 Jan 2023 |
Mission Therapeutics Successfully Completes First Clinical Assessment for Lead DUB Program, MTX652
|
|
06 Jan 2023 |
ArsenalBio Announces First Patient Dosed in Phase 1 Clinical Trial of AB-1015 in Development as a Treatment for Ovarian Cancer
|
|
06 Jan 2023 |
Nimble Therapeutics Announces Expansion of its Discovery and Development Partnership with Genentech
|
|
06 Jan 2023 |
Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease
|
|
06 Jan 2023 |
Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
|
|
06 Jan 2023 |
Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies
|
|
06 Jan 2023 |
UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review
|
|
06 Jan 2023 |
FDA Grants Priority Review to Genentech’s Bispecific Antibody Glofitamab for People With Relapsed or Refractory Large B-Cell Lymphoma
|
|
06 Jan 2023 |
CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs
|
|
05 Jan 2023 |
CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
|
|
05 Jan 2023 |
Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives
|
|
05 Jan 2023 |
Takeda Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
|
|
05 Jan 2023 |
Synaffix Enters License Agreement with Amgen to Build Next Generation ADCs
|
|
05 Jan 2023 |
Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
|
